These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 3621788)

  • 1. The debrisoquin hydroxylation phenotype does not predict the metabolism of phenytoin.
    Steiner E; Alván G; Garle M; Maguire JH; Lind M; Nilson SO; Tomson T; McClanahan JS; Sjöqvist F
    Clin Pharmacol Ther; 1987 Sep; 42(3):326-33. PubMed ID: 3621788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hydroxylation of desmethylimipramine: dependence on the debrisoquin hydroxylation phenotype.
    Spina E; Steiner E; Ericsson O; Sjöqvist F
    Clin Pharmacol Ther; 1987 Mar; 41(3):314-9. PubMed ID: 3816019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of DH/DL alleles regulating debrisoquine oxidation on phenytoin hydroxylation.
    Sloan TP; Idle JR; Smith RL
    Clin Pharmacol Ther; 1981 Apr; 29(4):493-7. PubMed ID: 7471615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in the inhibitory effect of cimetidine on desipramine metabolism between rapid and slow debrisoquin hydroxylators.
    Steiner E; Spina E
    Clin Pharmacol Ther; 1987 Sep; 42(3):278-82. PubMed ID: 3621781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype.
    Bertilsson L; Henthorn TK; Sanz E; Tybring G; Säwe J; Villén T
    Clin Pharmacol Ther; 1989 Apr; 45(4):348-55. PubMed ID: 2495208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between uptake and elimination of toluene and debrisoquin hydroxylation polymorphism.
    Löf A; Hansen SH; Näslund P; Steiner E; Wallén M; Hjelm EW
    Clin Pharmacol Ther; 1990 Mar; 47(3):412-7. PubMed ID: 2311341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype.
    von Bahr C; Movin G; Nordin C; Lidén A; Hammarlund-Udenaes M; Hedberg A; Ring H; Sjöqvist F
    Clin Pharmacol Ther; 1991 Mar; 49(3):234-40. PubMed ID: 2007317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. E- and Z-10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation.
    Mellström B; Bertilsson L; Säwe J; Schulz HU; Sjöqvist F
    Clin Pharmacol Ther; 1981 Aug; 30(2):189-93. PubMed ID: 7249504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin.
    Steiner E; Iselius L; Alván G; Lindsten J; Sjöqvist F
    Clin Pharmacol Ther; 1985 Oct; 38(4):394-401. PubMed ID: 4042522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings.
    Dahl-Puustinen ML; Lidén A; Alm C; Nordin C; Bertilsson L
    Clin Pharmacol Ther; 1989 Jul; 46(1):78-81. PubMed ID: 2743709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The metabolism of glyburide in subjects of known debrisoquin phenotype.
    Peart GF; Boutagy J; Shenfield GM
    Clin Pharmacol Ther; 1989 Mar; 45(3):277-84. PubMed ID: 2493353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymorphic debrisoquin hydroxylation in 757 Swedish subjects.
    Steiner E; Bertilsson L; Säwe J; Bertling I; Sjöqvist F
    Clin Pharmacol Ther; 1988 Oct; 44(4):431-5. PubMed ID: 3168394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Drug hydroxylation disorders (debrisoquin type) in a random sample of the Swiss population].
    Dick B; Küpfer A; Molnàr J; Braunschweig S; Preisig R
    Schweiz Med Wochenschr; 1982 Jul; 112(30):1061-7. PubMed ID: 7123181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stereochemistry of aromatic phenytoin hydroxylation in various drug hydroxylation phenotypes in humans.
    Fritz S; Lindner W; Roots I; Frey BM; Küpfer A
    J Pharmacol Exp Ther; 1987 May; 241(2):615-22. PubMed ID: 3572817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver microsomes.
    Spina E; Birgersson C; von Bahr C; Ericsson O; Mellström B; Steiner E; Sjöqvist F
    Clin Pharmacol Ther; 1984 Nov; 36(5):677-82. PubMed ID: 6488689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin.
    Sanz EJ; Villén T; Alm C; Bertilsson L
    Clin Pharmacol Ther; 1989 May; 45(5):495-9. PubMed ID: 2721104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Debrisoquin hydroxylation polymorphism among Ghanaians and Caucasians.
    Woolhouse NM; Andoh B; Mahgoub A; Sloan TP; Idle JR; Smith RL
    Clin Pharmacol Ther; 1979 Nov; 26(5):584-91. PubMed ID: 498701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impairment of phenytoin parahydroxylation as a cause of severe intoxication.
    de Wolff FA; Vermeij P; Ferrari MD; Buruma OJ; Breimer DD
    Ther Drug Monit; 1983 Jun; 5(2):213-5. PubMed ID: 6879646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-inheritance of the polymorphic metabolism of encainide and debrisoquin.
    Woosley RL; Roden DM; Dai GH; Wang T; Altenbern D; Oates J; Wilkinson GR
    Clin Pharmacol Ther; 1986 Mar; 39(3):282-7. PubMed ID: 3081292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquin metabolizers.
    Lennard MS; Tucker GT; Silas JH; Freestone S; Ramsay LE; Woods HF
    Clin Pharmacol Ther; 1983 Dec; 34(6):732-7. PubMed ID: 6641087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.